Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory ...

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

HRT may be safe for people with lupus in certain instances. One 2022 review involving 16 studies found that HRT can help ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells ...